Astellas – Pneumococcal Vaccine
Affinivax and Astellas have entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae (pneumococcus). The partnership will utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) – to advance a novel MAPS vaccine targeted to prevent and reduce the spread of pneumococcal disease. Astellas will lead and fully fund the development program and will obtain worldwide rights to commercialize the MAPS vaccine for pneumococcal disease. Affinivax will receive an initial upfront payment of $10 million from Astellas and will be eligible to receive a range of development milestones and commercial milestones. In addition, Affinivax will receive tiered royalties on any future product sales.
PATH – Pneumococcal Infections
Affinivax initiated a collaboration with PATH in early 2015 to help support the advancement of it lead MAPS vaccine candidate for Streptococcus pneumoniae (pneumococcal disease). The partnership includes funding from PATH to support product development, preclinical testing and manufacturing, with the goal to qualify and select a final development candidate to advance towards IND submission and clinical testing. PATH is an international nonprofit organization, focused on saving lives and improving health (especially among women and children) and supporting the acceleration of innovation across five platforms-vaccines, drugs, diagnostics, devices, and system and service innovations.
ClearPath / Astellas Pharma Inc. — Bacterial Nosocomial Infections
Affinivax initiated a collaboration with Nosocomial Vaccine Corporation (NVC) in October 2015 to develop MAPS vaccines to prevent bacterial nosocomial infections, also referred to as health-care associated infections. The collaboration includes funding from NVC sufficient to support the development of product candidates to advance towards clinical testing. NVC was established by ClearPath Development Company with the support of its partner, Astellas Pharma Inc.
The Bill & Melinda Gates Foundation
Affinivax is associated with The Bill & Melinda Gates Foundation, which made an investment in Affinivax at the company’s launch. This investment fits with the focus of the Foundation to identify and support the latest vaccine approaches that can impact global health by improving coverage, efficacy, safety and access to life-saving treatments. This commitment from the Bill & Melinda Gates Foundation includes additional investments in Affinivax based on the achievement of future success-based milestones.